Menu Search
Equities

Seres Therapeutics Inc

MCRB:NSQ

Seres Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6639
  • Today's Change-0.028 / -4.02%
  • Shares traded3.47m
  • 1 Year change-34.59%
  • Beta1.9708
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Seres Therapeutics Inc grew revenues 1,672.24% from 7.13m to 126.33m while net income improved from a loss of 250.16m to a smaller loss of 113.72m.
Gross margin--
Net profit margin-43,343.58%
Operating margin-42,211.23%
Return on assets-44.53%
Return on equity--
Return on investment-59.82%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Seres Therapeutics Inc fell by 35.07m. Cash Flow from Financing totalled 71.71m or 56.76% of revenues. In addition the company used 117.36m for operations while cash from investing totalled 10.58m.
Cash flow per share-1.12
Price/Cash flow per share--
Book value per share-0.5742
Tangible book value per share-0.5742
More ▼

Balance sheet in USDView more

Seres Therapeutics Inc has a Debt to Total Capital ratio of 664.68%, a higher figure than the previous year's 445.48%.
Current ratio1.38
Quick ratio0.889
Total debt/total equity--
Total debt/total capital6.65
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.